RxDoctor Payments Data

Robert Rogers, APRN

Acute Care · Louisville, KYNPI 1508854209

Payments from drug & device makers

$398in general payments, 2019–2025

Across 13 payments — averaging $30.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$145
  • Atricure, Inc.$93
  • Sanofi-aventis U.S. LLC$50
  • Johnson & Johnson$39
  • Boston Scientific$35
  • E.r. Squibb & Sons, L.L.C.$20
  • plus $16 from 1 others

What the payments were for

  • Food & beverage$398100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$398 in reported general payments places this provider in the 50th percentile of 319 acute care providers in Kentucky.

See all acute care providers in Kentucky

Medicare billing

Part B allowed, 2024
$137,784
Medicare patients
1,288
Services billed
6,421

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban1,041$1,039,264
XareltoRivaroxaban222$254,699
MultaqDronedarone Hcl20$43,402
Dofetilide150$23,751
Flecainide Acetate498$23,514
Propafenone Hcl ErPropafenone Hcl37$12,246
Metoprolol Succinate763$9,674
Amiodarone Hcl238$3,598
Diltiazem 24hr Er (Cd)Diltiazem Hcl149$3,061
Propafenone Hcl42$2,026
SotalolSotalol Hcl98$1,228
Diltiazem 24hr Er (Xr)Diltiazem Hcl14$1,120
Digoxin40$1,030
Diltiazem 24hr ErDiltiazem Hcl29$905
Carvedilol139$834

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$39$254,699222 claims
Sanofi-aventis U.S. LLCMultaq$50$43,40220 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 319 acute care providers in Kentucky.

Other acute care in Louisville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →